Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Orchestra BioMed Holdings (OBIO) EBITDA (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed EBITDA for 4 consecutive years, with -$20.8 million as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA fell 35.9% to -$20.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$75.2 million, a 30.68% decrease, with the full-year FY2024 number at -$61.0 million, down 24.1% from a year prior.
  • EBITDA was -$20.8 million for Q3 2025 at Orchestra BioMed Holdings, down from -$19.4 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$5.7 million in Q1 2022 to a low of -$20.8 million in Q3 2025.
  • A 4-year average of -$13.5 million and a median of -$13.3 million in 2023 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: tumbled 91.43% in 2023, then decreased 15.1% in 2024.
  • Orchestra BioMed Holdings' EBITDA stood at -$9.8 million in 2022, then plummeted by 30.67% to -$12.8 million in 2023, then fell by 27.06% to -$16.2 million in 2024, then fell by 28.38% to -$20.8 million in 2025.
  • Per Business Quant, the three most recent readings for OBIO's EBITDA are -$20.8 million (Q3 2025), -$19.4 million (Q2 2025), and -$18.8 million (Q1 2025).